The article outlines urgent research needs, such as the need for high-resolution exposure data, exploration of gene–environment interactions and molecular pathways, and the development of real-world and mechanistic studies assessing interventions. 

Read full article (European Heart Journal (2026) 00, 1–25) here!

This study aimed to assess whether JCAD serves as a novel marker of or target to address residual risk.

Read full article (European Heart Journal (2025) 00, 1–15) here!

Die kardiovaskuläre Bildgebung entwickelt sich zu einem zentralen Instrument der personalisierten Therapie der koronaren Herzkrankheit.

Lesen sie den vollständigen Artikel (Therapeutische Umschau 2026; 83 (3): 240–244) hier!
 

As the European Society of Cardiology (ESC) matured, the leadership looked beyond education, congresses, and scientific journals. Indeed, to serve its members and address its mission of reducing the burden of cardiovascular disease, it seemed necessary to raise its voice at the European level and its institutions in Brussels. 

Read the full article (European Heart Journal (2026) 00, 1–5) here!

This study aimed to investigate the association of baseline serum levels of CCN1, NT-proBNP, hsTnT, and PCSK9 with CMR-derived infarct characteristics assessed 30 days after acute STEMI in the intermediate post-infarction stage.

Read full article (IJC Heart & Vasculature 64 (2026) 101918) here!
 

High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker...

Read full article (European Heart Journal (2026) 47, 1799–1810) here!

Künstliche Intelligenz verbessert die Behandlung des Herzinfarktes. Florian A. Wenzl forscht intensiv daran, KI für die Risikoeinschätzung einzusetzen. 

Lesen Sie den vollständigen Artikel (Schweizerische Ärztezeitung, Jg. 107, Nr. 2, März 2026) hier!

Since the Beta-Blocker Heart Attack Trial in 1982, beta-blockers have been a cornerstone of therapy after myocardial infarction. Advances in the management of myocardial infarction in the past decades have prompted a reevaluation of early trials across the spectrum of left ventricular ejection fraction (LVEF).

Read full article (N ENGL J MED 394;6) here!

A recent study by Dr. Florian A. Wenzl and colleagues, published in The Lancet, applied artificial intelligence (AI) to population-representative data to develop a cancer-specific risk prediction tool: ONCO-ACS. The model predicts mortality, major bleeding, and ischaemic events – helping clinicians balance treatment benefits and risks.

Read full article (Lancet 2026; 407: 515–28) here!

Nicotine-containing products, whether combustible or smokeless, pose a growing threat to cardiovascular (CV) health. While tobacco smoking continues to cause millions of deaths annually, the rapid uptake of e-cigarettes, heated tobacco, and synthetic nicotine pouches,..., risks reversing decades of progress in tobacco control. 

Read full article (European Heart Journal (2025) 00, 1–18) here!